(Q35196196)

7 August 2017

1 reference

title

Factors affecting the clinical development of cytochrome p450 3A substrates (English)

1 reference

7 August 2017

Megan A Gibbs

1

1 reference

7 August 2017

Natilie A Hosea

series ordinal

2

1 reference

7 August 2017

1 January 2003

1 reference

Clinical Pharmacokinetics

7 August 2017

1 reference

7 August 2017

42

1 reference

7 August 2017

11

1 reference

7 August 2017

969-984

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200342110-00003

7 August 2017

0 references

cites work

Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test

1 reference

12 December 2020

Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

1 reference

12 December 2020

Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver

1 reference

12 December 2020

CYP3A gene expression in human gut epithelium

1 reference

12 December 2020

Bioavailability of terfenadine in man

1 reference

12 December 2020

Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro.

1 reference

12 December 2020

Felodipine kinetics in healthy men.

1 reference

12 December 2020

Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily

1 reference

12 December 2020

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole

1 reference

12 December 2020

Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach

1 reference

12 December 2020

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

1 reference

12 December 2020

Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.

1 reference

12 December 2020

The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.

1 reference

12 December 2020

Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues

1 reference

12 December 2020

Expression of cytochrome P450 3A in amphibian, rat, and human kidney

1 reference

12 December 2020

Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies

1 reference

12 December 2020

Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of [...]

1 reference

12 December 2020

Interaction between grapefruit juice and midazolam in humans.

1 reference

12 December 2020

In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions

1 reference

12 December 2020

Kinetics of drug metabolism inhibition: Use of metabolite concentration-time profiles

1 reference

12 December 2020

Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction

1 reference

12 December 2020

Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.

1 reference

12 December 2020

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

1 reference

12 December 2020

Characterization of human small intestinal cytochromes P-450.

1 reference

12 December 2020

Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans

1 reference

12 December 2020

Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin

1 reference

12 December 2020

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

1 reference

12 December 2020

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

1 reference

12 December 2020

Predicting drug interactions and pharmacokinetic variability with in vitro methods: the olanzapine experience

1 reference

12 December 2020

Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.

1 reference

12 December 2020

Human P-glycoprotein transports cyclosporin A and FK506.

1 reference

12 December 2020

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine

1 reference

12 December 2020

Bimodal distribution of renal cytochrome P450 3A activity in humans.

1 reference

12 December 2020

Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.

1 reference

12 December 2020

Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.

1 reference

12 December 2020

Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions

1 reference

12 December 2020

Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

1 reference

12 December 2020

Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells

1 reference

12 December 2020

In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A

1 reference

12 December 2020

Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam.

1 reference

12 December 2020

150 mg fluconazole does not substantially increase the effects of 10 mg midazolam or the plasma midazolam concentrations in healthy subjects.

1 reference

12 December 2020

Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver

1 reference

12 December 2020

Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes

1 reference

12 December 2020

Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture

1 reference

12 December 2020

Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.

1 reference

12 December 2020

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

1 reference

12 December 2020

Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.

1 reference

12 December 2020

Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities

1 reference

12 December 2020

The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine

1 reference

12 December 2020

Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism

1 reference

12 December 2020

Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers

1 reference

12 December 2020

Autoactivation and activation of the cytochrome P450s.

1 reference

12 December 2020

Cytochrome P-450 3A4: regulation and role in drug metabolism

1 reference

12 December 2020

First-pass metabolism of midazolam by the human intestine.

1 reference

12 December 2020

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

1 reference

12 December 2020

Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells.

1 reference

12 December 2020

Pharmacokinetic drug interactions with antimicrobial agents

1 reference

12 December 2020

Population pharmacokinetics of terfenadine

1 reference

12 December 2020

Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes

1 reference

12 December 2020

In vitro and in vivo drug interactions involving human CYP3A.

1 reference

12 December 2020

Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A

1 reference

12 December 2020

Atypical kinetic profiles in drug metabolism reactions

1 reference

12 December 2020

Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins.

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo

1 reference

12 December 2020

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

12 December 2020

Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro.

1 reference

12 December 2020

Can grapefruit juice influence ethinylestradiol bioavailability?

1 reference

12 December 2020

Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey

1 reference

12 December 2020

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

12 December 2020

The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

1 reference

12 December 2020

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

1 reference

12 December 2020

cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450

1 reference

12 December 2020

Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam

1 reference

12 December 2020

Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

1 reference

12 December 2020

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates

1 reference

12 December 2020

Clinically significant drug interactions with antituberculosis agents

1 reference

12 December 2020

Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability

1 reference

12 December 2020

Oxidation of quinidine by human liver cytochrome P-450

1 reference

12 December 2020

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

1 reference

12 December 2020

Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.

1 reference

12 December 2020

Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects

1 reference

12 December 2020

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

12 December 2020

Elucidation of distinct ligand binding sites for cytochrome P450 3A4

1 reference

12 December 2020

Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.

1 reference

12 December 2020

Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity.

1 reference

12 December 2020

Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3)

1 reference

12 December 2020

Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450

1 reference

12 December 2020

Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene

1 reference

12 December 2020

Inhibition and induction of human cytochrome P450 (CYP) enzymes

1 reference

12 December 2020

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

1 reference

12 December 2020

The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice

1 reference

12 December 2020

Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice

1 reference

12 December 2020

Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction

1 reference

12 December 2020

Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome P-450 in rats

1 reference

12 December 2020

Interindividual variability in inhibition and induction of cytochrome P450 enzymes

1 reference

12 December 2020

Cytochrome P450 3A: ontogeny and drug disposition

1 reference

12 December 2020

Characterization of Phase I and Phase II hepatic drug metabolism activities in a panel of human liver preparations

1 reference

12 December 2020

Sense and nonsense in the prediction of drug-drug interactions

1 reference

12 December 2020

In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse.

1 reference

12 December 2020

In vitro interaction between cyclosporin A and macrolide antibiotics

1 reference

12 December 2020

Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences

1 reference

12 December 2020

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity

1 reference

12 December 2020

Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nm-absorbing complex with cytochrome P-450

1 reference

12 December 2020

The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers

1 reference

12 December 2020

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

1 reference

12 December 2020

Pharmacokinetics of drugs that inactivate metabolic enzymes

1 reference

12 December 2020

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance

1 reference

12 December 2020

Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine

1 reference

12 December 2020

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression

1 reference

12 December 2020

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

1 reference

12 December 2020

Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin

1 reference

12 December 2020

Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily

1 reference

12 December 2020

10.2165/00003088-200342110-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

7 August 2017

1036904883

0 references

Fatcat ID

release_r6tcmtxdq5btvmlo57bk6fmmqq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/r6tcmtxdq5btvmlo57bk6fmmqq

24 November 2022

mapped directly with Wikidata item

1 reference